Squamous cell lung cancer
Conditions
Interventions
Nedaplatin plus S-1
Sponsors
Fukuoka University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient who had squamous lung cancer, neither surgery nor radiation indication, accompanied by anti-cancer chemotherapy 2. Informed consent is obtained 3.Patient who is judged as an appropriate case by the doctor in charge 4. PS0-1 5. No history of cardiac failure, renal failure, or liver damage.
Exclusion criteria
Exclusion criteria: 1. Patient who have severe infection 2. Pregnant or lactating women. 3. Multiple cancer 4. A known history of allergy 5. A known history of GI bleeding 6. Patient who have interstitial pneumonia 7. Patient who have severe diabetes mellitus, liver cirrhosis, renal dysfunction, angina pectoris, arrhythmia, or myocardiac infarction before 3 months 8. Patient who have therapeutic need of pleural effusion, pericardiac effusion, or SVC syndrome 9. Patient who have obscure symptoms of brain metastasis. 10. Patient who have obscure symptoms of peripheral nerve dysfunction 11. Patient who take flucytosin.of brain 12. Patient who have severe 13.patient who is judged as an inappropriate case by the doctor in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of recommended dose of nedaplatin in the case of combination with S-1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety, Drug adherence rate, response rate | — |
Countries
Japan
Contacts
Public ContactMasaki Fujita
Fukuoka University Hospital Respiratory Medicine
Outcome results
None listed